List of Excipients in Branded Drug SYMDEKO
SYMDEKO Excipient Strategy and Commercial Opportunities
SY明DEKO is a fixed-dose, two-tablet oral regimen containing tezacaftor and ivacaftor. Its excipient strategy prioritizes immediate-release tablet manufacture, gastrointestinal disintegration, film-coat identification, and oral absorption under high-fat dosing conditions. The largest commercial opportunities are in excipient supply, pediatric and swallowability adaptations, generic formulation development, analytical support, and manufacturing services rather than in a standalone excipient patent position.
What is SYMDEKO and how is its dosage form designed?
SYMDEKO contains two strengths administered on the same day:
| Component | Strength | Administration |
|---|---|---|
| Tezacaftor/ivacaftor tablet | 100 mg/150 mg | Morning |
| Ivacaftor tablet | 150 mg | Evening |
Patients take both products with fat-containing food. The high-fat requirement reflects the absorption characteristics of ivacaftor and tezacaftor, whose systemic exposure increases when administered with fat-containing meals (U.S. Food and Drug Administration [FDA], 2023).
The product is a conventional coated tablet rather than a capsule, oral suspension, granule, transdermal system, or injectable product. That design reduces manufacturing complexity and supports commercial scale, but it creates formulation challenges involving:
- Poor aqueous solubility of the active ingredients.
- Consistent dissolution across tablet lots.
- Tablet hardness and disintegration.
- Content uniformity for a combination product.
- Dose administration in pediatric patients.
- Sensitivity to food effects.
- Differentiation between the morning combination tablet and the evening ivacaftor tablet.
What excipients are used in SYMDEKO tablets?
The FDA prescribing information identifies the following inactive ingredients.
| Ingredient | Tezacaftor/ivacaftor tablet | Ivacaftor tablet | Primary formulation role |
|---|---|---|---|
| Microcrystalline cellulose | Yes | Yes | Diluent and compression aid |
| Croscarmellose sodium | Yes | Yes | Superdisintegrant |
| Sodium lauryl sulfate | Yes | Yes | Wetting and surfactant function |
| Magnesium stearate | Yes | Yes | Lubricant |
| Lactose monohydrate | No listed use | Yes | Diluent and tablet mass |
| Hypromellose acetate succinate | Yes | Not listed | Polymer supporting solubility and release control |
| Hypromellose | Film coat | Film coat | Film-forming polymer |
| Titanium dioxide | Film coat | Film coat | Opacifier and colorant |
| Talc | Film coat | Film coat | Anti-tacking and coating aid |
| Polyethylene glycol | Film coat | Film coat | Plasticizer |
| FD&C Blue No. 2 aluminum lake | Film coat | Film coat | Product identification colorant |
The FDA label identifies the ingredients but does not disclose the quantitative formula for each excipient. Commercial developers therefore cannot assume that an ingredient-for-ingredient match will produce equivalent dissolution, stability, or bioavailability (FDA, 2023).
Why is hypromellose acetate succinate strategically important?
Hypromellose acetate succinate, or HPMCAS, is the most technically distinctive excipient disclosed for the tezacaftor/ivacaftor tablet. HPMCAS is commonly used in enabling formulations for poorly soluble compounds because it can improve wetting, maintain supersaturation, and limit precipitation after dissolution.
Its presence indicates a formulation strategy that goes beyond basic tablet compression. The relevant commercial implications are:
- HPMCAS grade selection may affect dissolution and stability.
- Polymer particle size and substitution level can alter performance.
- Generic developers may need to qualify more than one grade or supplier.
- Changes in polymer source can trigger comparative dissolution and stability work.
- Excipient variability may create a practical manufacturing barrier even where no excipient patent applies.
HPMCAS should not automatically be treated as a patented feature of SYMDEKO. The presence of an excipient in the FDA label does not establish that the product owner has enforceable patent rights over the ingredient, grade, supplier, or use.
How does SYMDEKO’s excipient system support product performance?
The formulation uses a conventional functional architecture.
Solubility and wetting
Sodium lauryl sulfate provides surfactant activity that can improve wetting of hydrophobic drug particles. HPMCAS in the tezacaftor/ivacaftor tablet can support dissolution behavior for a poorly soluble active ingredient. These functions are important because incomplete dissolution can affect exposure and create a bioequivalence risk for a generic product.
Tablet strength and manufacturability
Microcrystalline cellulose provides bulk and compressibility. Magnesium stearate reduces adhesion to tooling and supports high-speed tableting. Excess lubricant, especially magnesium stearate, can slow wetting and dissolution, so blending time and lubricant concentration are critical process variables.
Disintegration
Croscarmellose sodium promotes tablet breakup after administration. The balance between tablet hardness, lubricant level, polymer content, and disintegrant performance can affect dissolution profiles.
Product identification
The blue film coating differentiates the tablets and helps distinguish the morning tezacaftor/ivacaftor dose from the evening ivacaftor dose. Color and imprint controls also reduce medication-error risk in a two-tablet regimen.
Food-effect management
The formulation does not eliminate the requirement for fat-containing food. Product development must therefore evaluate administration with a standardized high-fat meal and under relevant fed conditions. A generic product that matches dissolution in vitro but produces a materially different food effect could face regulatory difficulty.
What commercial opportunities exist for excipient suppliers?
The highest-value opportunity is supply into regulated, validated drug-product manufacturing. SYMDEKO’s excipient list contains several high-volume materials, but the technical opportunity differs by ingredient.
| Excipient category | Commercial opportunity | Competitive barrier |
|---|---|---|
| HPMCAS | Premium polymer supply, grade qualification, technical support | Performance variability and limited substitutability |
| Sodium lauryl sulfate | Commodity supply and low-cost dual sourcing | Broad supplier base and price competition |
| Croscarmellose sodium | Direct-compression and disintegration performance | Established global suppliers |
| Microcrystalline cellulose | High-volume tablet excipient supply | Commodity economics |
| Magnesium stearate | Pharmaceutical-grade lubrication | Supplier qualification and impurity controls |
| Film-coat materials | Pre-mixed coating systems and color matching | Regulatory consistency and color control |
| Lactose monohydrate | Supply for the ivacaftor tablet | Commodity product with established alternatives |
HPMCAS offers the strongest technical differentiation. Suppliers can compete through:
- Consistent substitution profiles.
- Controlled particle-size distribution.
- Low bioburden and low elemental impurity profiles.
- Reliable supply under pharmaceutical quality systems.
- Formulation-development support.
- Documentation for supplier changes and comparability assessments.
A supplier that replaces an incumbent excipient must support change control, stability data, extractables and leachables assessments where relevant, and regulatory documentation for the drug-product manufacturer.
What generic formulation opportunities exist for SYMDEKO?
A generic developer could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence for the relevant tablet strengths. The central technical issue is not simply reproducing the inactive-ingredient list. It is matching the product’s performance.
Key development work would include:
- Quantitative composition screening.
- Comparative dissolution across multiple pH conditions.
- Fed and fasting pharmacokinetic studies where required.
- Tablet hardness and disintegration studies.
- Stability under long-term and accelerated conditions.
- Evaluation of HPMCAS grade and supplier changes.
- Assessment of color, imprint, and packaging differences.
- Evaluation of dose administration with fat-containing food.
A generic developer may seek a qualitatively and quantitatively different formulation if FDA requirements permit it. That approach can reduce dependence on a particular excipient supplier but may increase bioequivalence and dissolution risk.
What are the main generic launch risks?
The principal risks are:
- Formulation patents covering the tablet composition or manufacturing process.
- Method-of-use patents covering treatment of cystic fibrosis in defined patient populations.
- Regulatory exclusivity or pediatric exclusivity.
- Failure to match fed exposure.
- Difficulty reproducing the dissolution effect associated with HPMCAS.
- Patent litigation after a Paragraph IV certification.
- Supply-chain dependence on qualified pharmaceutical-grade excipients.
A generic launch date cannot be inferred from the public ingredient list. It depends on the current Orange Book patent listings, patent-term adjustments, pediatric extensions, litigation outcomes, settlement terms, and any later-listed patents.
What patents protect SYMDEKO?
SYMDEKO’s patent protection is expected to involve several layers:
| Patent layer | Potential subject matter | Relevance to excipient strategy |
|---|---|---|
| Active ingredient patents | Tezacaftor, ivacaftor, or related chemical matter | Usually the primary exclusivity layer |
| Combination patents | Tezacaftor plus ivacaftor | Protects the regimen or combination |
| Formulation patents | Tablet composition, solid dispersion, polymers, or dissolution profile | Directly relevant to excipient design |
| Method-of-use patents | Treatment of CFTR mutations or cystic fibrosis | Can delay generic use for protected indications |
| Manufacturing patents | Preparation of active ingredients or dosage forms | Can restrict supply routes |
| Pediatric or population claims | Age, mutation, or treatment subgroup | Relevant to labeling and carve-out strategy |
The FDA Orange Book is the controlling public source for listed drug patents and exclusivity associated with an approved small-molecule product (FDA, 2024a). Patent claims must be reviewed individually. A patent that mentions HPMCAS or another excipient may claim a narrow formulation, a broad dosage form, a process, or a particular dissolution result. The mere presence of the ingredient in the commercial product does not establish infringement.
When does SYMDEKO lose exclusivity?
SY明DEKO exclusivity is not determined by one date. Relevant dates include:
- New chemical entity exclusivity, if applicable to the approved active ingredient.
- Five-year or other statutory exclusivity associated with the NDA.
- Three-year exclusivity for certain new clinical investigations.
- Pediatric exclusivity.
- Orange Book-listed patent expiration dates.
- Patent-term adjustments.
- Patent-term extensions.
- Paragraph IV litigation outcomes.
- Settlement agreements between the brand company and generic applicants.
FDA approved SYMDEKO in February 2018 under NDA 210491 (FDA, 2018). The first commercial generic-entry opportunity depends on the live patent and litigation record, not solely on the approval date. Any current exclusivity assessment should use the latest Orange Book entry and court docket information.
What is the FDA regulatory status and Orange Book position?
SYMDEKO is an FDA-approved prescription product for cystic fibrosis patients with qualifying CFTR mutations. It is regulated as a small-molecule drug under an NDA, not as a biologic. Biosimilar pathways therefore do not apply.
The Orange Book is relevant because an ANDA applicant must address listed patents through one of four certifications:
- Paragraph I: no patent information is listed.
- Paragraph II: the listed patent has expired.
- Paragraph III: the applicant will wait until patent expiration.
- Paragraph IV: the listed patent is invalid, unenforceable, or will not be infringed.
A Paragraph IV notice can trigger patent litigation and a potential 30-month stay of ANDA approval under applicable statutory conditions (FDA, 2024b). The commercial result can be an at-risk launch, a licensed entry date, or delayed market entry.
How strong is the SYMDEKO patent estate from an excipient perspective?
The excipient position is likely strongest where claims connect the inactive ingredient to a defined technical result, such as:
- A specific polymer and drug ratio.
- A defined dissolution profile.
- A solid dispersion or amorphous composition.
- A controlled precipitation or supersaturation profile.
- A manufacturing process that produces a specific dosage form.
- A combination of particle-size, polymer, and release parameters.
The position is weaker where a claim only lists conventional excipients without functional limitations. Generic developers can often design around a named ingredient by changing polymer grade, replacing a diluent, altering the coating system, or using a different manufacturing process, subject to bioequivalence and patent constraints.
What licensing and partnership opportunities exist?
The most credible licensing opportunities are technical rather than brand-asset licenses.
Excipient and formulation technology licenses
Opportunities include:
- HPMCAS-based solubility-enhancement platforms.
- Polymer screening and formulation-development services.
- Ready-to-use film-coating systems.
- Taste-masking and pediatric tablet technologies.
- Continuous manufacturing or process-control platforms.
- Analytical methods for dissolution and solid-state characterization.
Generic development partnerships
A generic company may license:
- A prequalified HPMCAS formulation.
- A bioequivalence-ready formulation package.
- A non-infringing manufacturing process.
- Regional rights for selected markets.
- A formulation with an alternative excipient system.
Regional commercialization
CFTR modulator access varies by jurisdiction, reimbursement system, mutation prevalence, and local patent rights. Regional opportunities may arise in markets where:
- Patent rights expire earlier.
- Local manufacturing is favored.
- Public procurement rewards lower-cost versions.
- Pediatric access is underdeveloped.
- Regulatory pathways allow reliance on established foreign data.
A licensee must still assess local patent registers, data exclusivity, compulsory-license rules, import restrictions, and regulatory requirements.
How does SYMDEKO compare with other Vertex cystic fibrosis products?
| Product | Core active ingredients | Dosage-form implication | Excipient opportunity |
|---|---|---|---|
| KALYDECO | Ivacaftor | Ivacaftor tablet or granule presentations | Pediatric granules and solubility-focused products |
| ORKAMBI | Lumacaftor/ivacaftor | Combination tablet and granule products | High complexity from dual-active formulation |
| SYMDEKO | Tezacaftor/ivacaftor plus ivacaftor | Two-tablet daily regimen | HPMCAS and tablet differentiation |
| TRIKAFTA | Elexacaftor/tezacaftor/ivacaftor plus ivacaftor | Two-tablet daily regimen | Combination-product and pediatric adaptation opportunities |
SYMDEKO has a less complex active-ingredient profile than TRIKAFTA but retains the operational burden of two differently composed tablets. TRIKAFTA has greater commercial importance for Vertex’s CF franchise, while SYMDEKO remains relevant to patients, regional markets, legacy treatment pathways, and future generic formulation work.
What revenue exposure is linked to SYMDEKO?
Public company reporting generally emphasizes the broader cystic fibrosis product franchise rather than disclosing a standalone SYMDEKO revenue line. Revenue exposure should therefore be assessed through:
- Product-specific sales disclosures where available.
- Declines following migration to TRIKAFTA.
- Patient conversion rates.
- Geographic reimbursement coverage.
- Eligible mutation populations.
- Generic-entry timing.
- Net price and rebate changes.
The commercial value of SYMDEKO is likely more concentrated in residual and regional demand than in the growth profile of newer CFTR combinations. That makes excipient opportunities more relevant to cost reduction, generic entry, lifecycle management, and supply assurance than to premium brand expansion.
Key Takeaways
- SYMDEKO uses conventional tablet excipients plus HPMCAS in the tezacaftor/ivacaftor tablet.
- HPMCAS is the most technically differentiated excipient and the strongest target for formulation development and supplier competition.
- Sodium lauryl sulfate, croscarmellose sodium, microcrystalline cellulose, magnesium stearate, lactose, and film-coat materials support wetting, compression, disintegration, lubrication, and product identification.
- FDA labeling discloses excipient identity but not quantitative composition.
- Generic developers must match dissolution, food-effect performance, stability, and bioequivalence rather than merely copy the qualitative ingredient list.
- SYMDEKO is a small-molecule drug, so biosimilar pathways do not apply.
- Paragraph IV challenges and launch timing depend on current Orange Book listings, patent litigation, exclusivity, and settlement terms.
- The strongest commercial opportunities are HPMCAS supply, formulation services, pediatric adaptations, generic development, analytical testing, and regional licensing.
- The product’s excipient list alone does not establish a patent barrier.
FAQs
Can a generic SYMDEKO use different excipients?
Yes, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, dissolution, stability, labeling, and patent compliance. A different excipient system may create additional development risk if it changes exposure or food-effect behavior.
Is HPMCAS required to make a generic SYMDEKO?
Not necessarily. HPMCAS is disclosed in the reference product, but an ANDA applicant may seek an alternative formulation if it can demonstrate equivalent performance and avoid applicable patent claims.
Does SYMDEKO have biosimilar competition?
No. SYMDEKO contains small-molecule active ingredients and is approved under an NDA. Competition would generally proceed through generic drug pathways rather than the biosimilar pathway.
Could pediatric granules replace SYMDEKO tablets?
A pediatric granule product could improve administration for younger or swallowing-impaired patients, but it would require a separate formulation and regulatory strategy. The product would need to address dose flexibility, taste, food administration, stability, and bioequivalence or other applicable FDA requirements.
Which excipient creates the greatest supply-chain risk?
HPMCAS is the most likely technical supply-chain pressure point because grade, substitution profile, particle characteristics, and performance can affect dissolution. Commodity excipients have broader supplier options but still require pharmaceutical qualification and change-control management.
References
-
U.S. Food and Drug Administration. (2018). FDA approves new treatment for cystic fibrosis. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-cystic-fibrosis
-
U.S. Food and Drug Administration. (2023). SYMDEKO prescribing information. Vertex Pharmaceuticals Incorporated. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024b). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information-drugs
-
U.S. Food and Drug Administration. (2020). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biostudies-pharmacokinetic-endpoints-drugs-submitted-anda-guidance-industry
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
Visit the Subscription Options page for details on plans and pricing.
ISSN: 2162-2639

Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Access the Complete Database
Make Better Decisions
- Uncover prior art in expired and abandoned patents
- Obtain formulation and manufacturing information
- Drug patents in 130+ countries